Results 121 to 130 of about 20,268 (224)

Focus on HFpEF in heart failure

Chinese Medical Journal, 2022
Chunhui He, Rongchong Huang, Ningning Wang   +2 more
openaire   +3 more sources

Comparative effectiveness of pharmacotherapy for heart failure with preserved ejection fraction: A systematic review and network meta‐analysis

Diabetes, Obesity and Metabolism, Volume 28, Issue 4, Page 3137-3145, April 2026.
Abstract Aim Heart failure with preserved ejection fraction (HFpEF) presents a therapeutic challenge, characterised by a paucity of validated treatments. Emerging data suggest that targeting adiposity is central to HFpEF pathogenesis. We conducted an updated network meta‐analysis to compare the efficacy of emerging and established HFpEF therapies ...
Szu‐Han Chen, Yu‐Wen Tseng, Chi‐Jung Huang, Shu‐Mei Yang, Marat Fudim, Shao‐Yuan Chuang, Shih‐Hsien Sung, Hao‐Min Cheng   +7 more
wiley   +1 more source

Metabolic rewiring through succinate-GPR91 signaling: a fresh perspective on HFpEF energetics. [PDF]

Cardiovasc Diabetol
Telesca M, Masciovecchio V, Costantino S.   +2 more
europepmc   +1 more source

Osteopontin in HFpEF

Journal of the American College of Cardiology, 2019
Fadi N. Salloum, Vinh Q. Chau
openaire   +1 more source

Risk stratification using coronary artery calcium and potential benefit of semaglutide therapy: A cost‐effectiveness modelling study

Diabetes, Obesity and Metabolism, Volume 28, Issue 4, Page 3229-3237, April 2026.
Abstract Aim Coronary artery calcium (CAC) scoring is observed to improve risk stratification for major adverse cardiovascular events (MACE). Semaglutide, a recently introduced anti‐obesity drug, is very effective, but wider use is limited due to high costs.
Sai Rahul Ponnana, Tong Zhang, Santosh Kumar Sirasapalli, Zhuo Chen, Jean‐Eudes Dazard, Niketh Surya, Shamsa Elhussain, Kanimozhi Sivanantham, Robert Okyere, Ian J. Neeland, Sanjay Rajagopalan, Salil V. Deo   +11 more
wiley   +1 more source

Molecular Signature of HFpEF

JACC: Basic to Translational Science, 2021
Andrew A. Gibb, Emma K. Murray, Deborah M. Eaton, Anh T. Huynh, Dhanendra Tomar, Joanne F. Garbincius, Devin W. Kolmetzky, Remus M. Berretta, Markus Wallner, Steven R. Houser, John W. Elrod   +10 more
openaire   +1 more source

The urinary albumin‐to‐creatinine ratio can direct personalized prevention and treatment for cardiovascular and chronic kidney disease

Journal of Internal Medicine, Volume 299, Issue 4, Page 444-466, April 2026.
Abstract Increased urinary albumin excretion is a strong predictor for cardiovascular events in persons with and without decreased glomerular filtration rate and can be assessed with the urinary albumin‐to‐creatinine ratio (UACR), which is a selective, sensitive, and convenient method for patients.
Holly J. Kramer, George L. Bakris
wiley   +1 more source

Prognostic Utility of the HFpEF-ABA Score for HFpEF Patients: Insights From the TOPCAT Trial. [PDF]

JACC Adv
Zhu W, Guo L, Chen X, Ye M.
europepmc   +1 more source

Diagnosing HFpEF

JACC: Cardiovascular Imaging, 2018
openaire   +1 more source

GLP‐1 Receptor Agonists for the Prevention of New‐Onset Heart Failure: A Systematic Review and Meta‐Analysis of Placebo‐Controlled Randomized Clinical Trials

Obesity Reviews, Volume 27, Issue 4, April 2026.
ABSTRACT Introduction Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) improve outcomes in heart failure (HF) with preserved ejection fraction. Whether GLP‐1 RA prevent new‐onset HF in Type 2 diabetes or obesity requires further investigation. Methods We performed an updated meta‐analysis of randomized placebo‐controlled trials (RCT) of treatment ...
João Sérgio Neves, Carolina B. Lobato, Ana Rita Leite, Catarina Vale, Francisco Vasques‐Nóvoa, Francisca Saraiva, Adelino Leite‐Moreira, Jens J. Holst, João Pedro Ferreira   +8 more
wiley   +1 more source